2012-11-13 21:29:58 -
MINNEAPOLIS - November 13, 2012 - The Federal Circuit Court of Appeals has
affirmed the April 2010 jury verdict from the Federal District Court of Delaware
that the CoreValve® System infringed a single Andersen patent held by Edwards
Lifesciences. The Court of Appeals also remanded the case back to the District
Court to consider a potential injunction. While Medtronic respects the court's
ruling, we respectfully disagree with this conclusion and we are evaluating next
These legal actions have no impact on the Medtronic CoreValve U.S. Pivotal
Trial, the Medtronic CoreValve SURTAVI Trial, or any other clinical studies
evaluating the CoreValve System. Due to its global manufacturing capabilities,
Medtronic does not anticipate any interruption to the global supply of the
Medtronic CoreValve System.
While Edwards has applied for a patent extension, there
is no assurance an
extension will be issued or what the impact or duration of that extension would
be. These applications involve a review by two government agencies, and the
process often can take between 2 and 5 years.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global
leader in medical technology - alleviating pain, restoring health, and extending
life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from anticipated
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medtronic, Inc. via Thomson Reuters ONE